Startup profile for Erasca: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Erasca funding, valuation and investors

Clinical-stage oncology company developing therapies that shut down multiple cancer growth pathways simultaneously.

Keep track of Erasca

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series B

$200M · April 2020

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$200M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

public

public

Investors in latest funding

Lead: ARCH Venture Partners

Other: Andreessen Horowitz

Latest tracked event: IPO (July 2021). It is shown separately because it is not counted as disclosed equity funding.

Sources: latest funding Last verified: 2026-07-25

Overview

Erasca develops small-molecule and biologic oncology therapies aimed at shutting down the RAS/MAPK pathway and related cancer signaling networks. The company went public on NASDAQ (ERAS) in July 2021 after a $200M Series B co-led by ARCH Venture Partners.

Why Erasca is interesting

Founded by Ignyta alum Jonathan Lim, Erasca raised one of 2020's largest biotech rounds ($200M Series B) to pursue multi-pathway cancer drugging beyond single-target bets, then listed on NASDAQ as ERAS in 2021.

Product & use cases

Clinical-stage oncology therapies targeting the MAPK signaling pathway for solid tumors.

  • Clinical trials for MAPK-pathway solid tumors
  • Combination therapy against drug-resistant cancers
  • Pipeline expansion via in-licensing

Key facts

  • Series B (Apr 2020): $200M co-led by ARCH Venture Partners (/fund/arch-venture-partners) and Cormorant Asset Management
  • IPO (Jul 2021): Listed on NASDAQ as ERAS
  • Thesis: multi-pathway oncology drugging targeting RAS/MAPK and related cancer signaling

Funding history (newest first)

IPO

2021-07 Undisclosed

Source: https://www.nasdaq.com/market-activity/stocks/eras

Series B

2020-04 $200M

Source: https://www.prnewswire.com/news-releases/erasca-raises-200-million-series-b-financing-301042785.html

Investors in our directory

Funds linked from Erasca's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz ARCH Venture Partners

Competitive landscape

Edge: Multi-pathway shutdown thesis with ARCH and a16z life sciences backing; public-market capital access post-IPO.

MAPK-pathway oncology is crowded. Erasca's combination-therapy thesis differentiates from single-target approaches; clinical validation is the entire game as a public biotech.

  • Amgen incumbent

    Large pharma oncology portfolios.

  • Revolution Medicines direct

    RAS-pathway oncology competitor.

  • Mirati (BMS) adjacent

    KRAS inhibitor leader; overlapping MAPK ecosystem.

Notable stories

  • Erasca reached NASDAQ (ERAS) in July 2021 roughly three years after founding.
  • Company name derives from 'erasing cancer' — shutting down multiple growth pathways.

Industries

Biotech & Life Sciences

Market / IPO context

Ticker: ERAS (NASDAQ)

IPO status: public

IPO date: 2021-07

Editorial / static context — not a live quote.

Related funding articles

Venture Capital Tracker pieces that cover Erasca's financing or category context.

FAQs about Erasca

Practical answers founders, operators, and investors typically search for.

Erasca is a clinical-stage biotech developing oncology therapies that target multiple cancer growth pathways, with a focus on shutting down RAS/MAPK signaling networks.
Erasca's $200M Series B was co-led by ARCH Venture Partners (/fund/arch-venture-partners). Andreessen Horowitz (/fund/andreessen-horowitz) is also listed among its backers.
Erasca went public on NASDAQ (ticker ERAS) in July 2021 after its Series B. It is now a publicly traded biotech company.
It bets that shutting down multiple cancer pathways simultaneously can succeed where single-target drugs fail — a thesis backed by one of 2020's largest private biotech rounds.
Erasca is public. It trades on NASDAQ under the ticker ERAS.
ERAS on NASDAQ.
July 2021.
Both target RAS/MAPK cancers; Erasca emphasizes combination therapies.
All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.